- $605.38m
- $422.26m
Brief: Eliem Therapeutics Provides ETX-810 Program Update
Brief: Eliem Therapeutics Believes Its Cash, Cash Equivalents Of $149.9 Million Are Sufficient To Fund Key Pipeline Catalysts And Operations Until Mid-2024
Brief: Eliem Announces Updated Development Plans And The Advancement Of Etx-155 For The Treatment Of Major Depressive Disorder
Brief: Eliem Therapeutics Announces Last Patient Completed Dosing In Phase 2A Study Of ETX-810 In Patients With Lumbosacral Radicular Pain (LSRP)
Brief: Eliem Therapeutics - Current Cash, Cash Equivalents Expected To Fund Operations Through At Least 2023
U.S. RESEARCH ROUNDUP-Darling Ingredients, Live Nation Entertainment, Natera
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:43 AM
Eliem Therapeutics plunges as nerve damage pain drug fails trial
NASDAQ RESUMED AT 07:30 AM
Brief: Eliem Provides Update On ETX-810 And ETX-155 Clinical Programs
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Eliem Therapeutics Says Current Cash And Marketable Securities To Fund Ops Till Late 2023
Brief: Eliem Therapeutics Provides Program Updates And An Overview Of Expected Near-Term Milestones
U.S. STOCKS ON THE MOVE-Tesla, McDonald's, Wolfspeed
Guggenheim sees opportunities within neurology, immunology spaces in 2022
Brief: Eliem Therapeutics Reports Q3 Financial And Business Highlights
Brief: Eliem Therapeutics Reports Second Quarter Financial Results
Guggenheim starts Eliem Therapeutics with 'buy' on lead asset's strong potential
NASDAQ RESUMED AT 09:49 AM